AlphAIAlphAI — Financial news for AI agents
stocktitan.netNOV 32 min read$RVTY

Revvity forecasts about $2.86 billion in 2026 revenue, excluding its China diagnostics business.

Revvity reported Q3 2026 pro forma revenue of $729M, up 7% YoY, with adjusted EPS of $0.60. The company raised full-year guidance, forecasting $2.86B in 2026 revenue. CEO Prahlad Singh highlighted strong performance and growth momentum. Investor Day is scheduled for November 13, 2026.

Original reporting
stocktitan.net
Published Nov 3, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RVTY
Bullish
high confidence
Mentioned
$RVTY
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

The new revenue forecast signals a stronger recovery and may prompt analysts to raise price targets.

02

Market read

First‑report guidance for a mid‑cap biotech‑instrumentation firm; material for traders seeking exposure to health‑science equipment.

03

What to watch

Potential supply‑chain constraints and regulatory risks could temper the revenue outlook.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Revvity, a provider of health‑science solutions, released its Q3 2026 results and full‑year guidance.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Revvity issued 2026 revenue guidance of approximately $2.86 billion, excluding its China diagnostics business.

Expected impact

likely upside as market absorbs stronger revenue outlook

Evidence & confidence

Revenue guidance is a material, first‑report fact; the amount is sizable for a mid‑cap biotech‑instrumentation firm.

Market effects

Sector

Higher Revvity guidance may boost sentiment in the life‑sciences instrumentation sector.

Regional

U.S. biotech and diagnostics stocks could see modest gains.

Global

Limited to markets tracking U.S. health‑science equipment makers.

Counterpoint

What could challenge this read

If the China diagnostics exclusion reduces long‑term growth, the guidance may be overstated.

Key entities

  • company
    Revvity Inc.

    U.S. listed health‑science solutions provider.

  • executive
    Prahlad Singh

    President and CEO of Revvity, quoted on the guidance.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

3 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

tradingpedia.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min